Guggenheim Reaffirms Buy Rating for Dyne Therapeutics (NASDAQ:DYN)
Dyne Therapeutics (NASDAQ:DYN – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at Guggenheim in a research note issued on Wednesday,Benzinga reports. They currently have a $50.00 price objective on the stock. Guggenheim’s target price would indicate a potential upside of 363.82% from the company’s previous close. Several other equities analysts […]
Dyne Therapeutics (NASDAQ:DYN – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at Guggenheim in a research note issued on Wednesday,Benzinga reports. They currently have a $50.00 price objective on the stock. Guggenheim’s target price would indicate a potential upside of 363.82% from the company’s previous close. Several other equities analysts […]
